[1] Brennan KC, Pietrobon D. A systems neuroscience approach to migraine. Neuron 2018;97:1004–21. https://doi.org/10.1016/j.neuron.2018.01.029.
[2] Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain. Pain 2013;154:44–53. https://doi.org/10.1016/j.pain.2013.07.021.
[3] Harriott AM, Strother LC, Vila-Pueyo M, Holland PR. Animal models of migraine and experimental techniques used to examine trigeminal sensory processing. J Headache Pain 2019;20:91–106. https://doi.org/10.1186/s10194-019-1043-7.
[4] Romero-Reyes M, Uyanik JM. Orofacial pain management: current perspectives. J Pain Res 2014;7:99–115. https://doi.org/10.2147/JPR.S37593.
[5] Tajti J, Párdutz A, Vámos E, Tuka B, Kuris A, Bohár Z, et al. Migraine is a neuronal disease. J Neural Transm (Vienna) 2011;118:511–24. https://doi.org/10.1007/s00702-010-0515-3.
[6] Aczél T, Kun J, Szőke É, Rauch T, Junttila S, Gyenesei A, et al. Transcriptional alterations in the trigeminal ganglia, nucleus and peripheral blood mononuclear cells in a rat orofacial pain model. Front Mol Neurosci 2018;11:219–32. https://doi.org/10.3389/fnmol.2018.00219.
[7] Iwata K, Takeda M, Oh SB, Shinoda M. Neurophysiology of orofacial pain. In: Farah CS, Balasubramaniam R, McCullough MJ, editors. Contemporary Oral Medicine, Springer International Publishing; 2017. p. 1–23. https://doi.org/10.1007/978-3-319-28100-1_8-1.
[8] Lukács M, Haanes KA, Majláth Z, Tajti J, Vécsei L, Warfvinge K, et al. Dural administration of inflammatory soup or Complete Freund’s Adjuvant induces activation and inflammatory response in the rat trigeminal ganglion. J Headache Pain 2015;16:564–75. https://doi.org/10.1186/s10194-015-0564-y.
[9] Körtési T, Tuka B, Nyári A, Vécsei L, Tajti J. The effect of orofacial complete Freund’s adjuvant treatment on the expression of migraine-related molecules. J Headache Pain 2019;20:43–52. https://doi.org/10.1186/s10194-019-0999-7.
[10] Kopach O, Viatchenko-Karpinski V, Belan P, Voitenko N. Development of inflammation-induced hyperalgesia and allodynia is associated with the upregulation of extrasynaptic AMPA receptors in tonically firing lamina II dorsal horn neurons. Front Physiol 2012;3:391–99. https://doi.org/10.3389/fphys.2012.00391.
[11] Park JS, Yaster M, Guan X, Xu JT, Shih MH, Guan Y, et al. Role of spinal cord alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors in complete Freund’s adjuvant-induced inflammatory pain. Mol Pain 2008;4:67–78. https://doi.org/10.1186/1744-8069-4-67.
[12] Park JS, Voitenko N, Petralia RS, Guan X, Xu JT, Steinberg JP, et al. Persistent inflammation induces GluR2 internalization via NMDA receptor-triggered PKC activation in dorsal horn neurons. J Neurosci 2009;29:3206–19. https://doi.org/10.1523/JNEUROSCI.4514-08.2009.
[13] Zhang B, Tao F, Liaw WJ, Bredt DS, Johns RA, Tao YX. Effect of knock down of spinal cord PSD-93/chapsin-110 on persistent pain induced by complete Freund’s adjuvant and peripheral nerve injury. Pain 2003;106:187–96. https://doi.org/10.1016/j.pain.2003.08.003.
[14] Imbe H, Iwata K, Zhou QQ, Zou S, Dubner R, Ren K. Orofacial deep and cutaneous tissue inflammation and trigeminal neuronal activation. Implications for persistent temporomandibular pain. Cells Tissues Organs 2001;169:238–47. https://doi.org/10.1159/000047887.
[15] Okumura M, Iwata K, Yasuda K, Inoue K, Shinoda M, Honda K, et al. Alternation of gene expression in trigeminal ganglion neurons following complete Freund’s adjuvant or capsaicin injection into the rat face. J Mol Neurosci 2010;42:200–09. https://doi.org/10.1007/s12031-010-9348-7.
[16] Chung MK, Park J, Asgar J, Ro JY. Transcriptome analysis of trigeminal ganglia following masseter muscle inflammation in rats. Mol Pain 2016;12:1–12. https://doi.org/10.1177/1744806916668526.
[17] Puehler W, Rittner HL, Mousa SA, Brack A, Krause H, Stein C, et al. Interleukin-1 beta contributes to the upregulation of kappa opioid receptor mrna in dorsal root ganglia in response to peripheral inflammation. Neuroscience 2006;141:989–98. https://doi.org/10.1016/j.neuroscience.2006.03.078.
[18] Wu SX, Zhu M, Wang W, Wang YY, Li YQ, Yew DT. Changes of the expression of 5-HT receptor subtype mRNAs in rat dorsal root ganglion by complete Freund’s adjuvant-induced inflammation. Neuroscience Letters 2001;307:183–86. https://doi.org/10.1016/S0304-3940(01)01946-2.
[19] Luo H, Cheng J, Han JS, Wan Y. Change of vanilloid receptor 1 expression in dorsal root ganglion and spinal dorsal horn during inflammatory nociception induced by complete Freund’s adjuvant in rats. Neuroreport 2004;15:655–58. https://doi.org/10.1097/00001756-200403220-00016.
[20] Demartini C, Tassorelli C, Zanaboni AM, Tonsi G, Francesconi O, Nativi C, et al. The role of the transient receptor potential ankyrin type-1 (TRPA1) channel in migraine pain: evaluation in an animal model. J Headache Pain 2017;18:94–103. https://doi.org/10.1186/s10194-017-0804-4.
[21] Takeda M, Tanimoto T, Kadoi J, Nasu M, Takahashi M, Kitagawa J, et al. Enhanced excitability of nociceptive trigeminal ganglion neurons by satellite glial cytokine following peripheral inflammation. Pain 2007;129:155–66. https://doi.org/10.1016/j.pain.2006.10.007.
[22] Krzyzanowska A, Avendaño C. Behavioral testing in rodent models of orofacial neuropathic and inflammatory pain. Brain Behav 2012;2:678–97. https://doi.org/10.1002/brb3.85.
[23] Peres MFP, Zukerman E, Senne Soares CA, Alonso EO, Santos BFC, Faulhaber MHW. Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia 2004;24:735–39. https://doi.org/10.1111/j.1468-2982.2004.00750.x.
[24] Martínez F, Castillo J, Rodríguez JR, Leira R, Noya M. Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks. Cephalalgia 1993;13:89–93. https://doi.org/10.1046/j.1468-2982.1993.1302089.x.
[25] Ferrari MD, Odink J, Bos KD, Malessy MJ, Bruyn GW. Neuroexcitatory plasma amino acids are elevated in migraine. Neurology 1990;40:1582–86. https://doi.org/10.1212/WNL.40.10.1582
[26] Cananzi AR, D’Andrea G, Perini F, Zamberlan F, Welch KM. Platelet and plasma levels of glutamate and glutamine in migraine with and without aura. Cephalalgia 1995;15:132–5. https://doi.org/10.1046/j.1468-2982.1995.015002132.x.
[27] Campos F, Sobrino T, Pérez-Mato M, Rodríguez-Osorio X, Leira R, Blanco M, et al. Glutamate oxaloacetate transaminase: a new key in the dysregulation of glutamate in migraine patients. Cephalalgia 2013;33:1148–54. https://doi.org/10.1177/0333102413487444.
[28] Guerriero RM, Giza CC, Rotenberg A. Glutamate and GABA imbalance following traumatic brain injury. Curr Neurol Neurosci Rep 2015;15:27–38. https://doi.org/10.1007/s11910-015-0545-1.
[29] Knyihár-Csillik E, Chadaide Z, Okuno E, Krisztin-Péva B, Toldi J, Varga C, et al. Kynurenine aminotransferase in the supratentorial dura mater of the rat: effect of stimulation of the trigeminal ganglion. Exp Neurol 2004;186:242–47. https://doi.org/10.1016/j.expneurol.2003.12.001.
[30] Vámos E, Párdutz Á, Varga H, Bohár Z, Tajti J, Fülöp F, et al. L-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus. Neuropharmacology 2009;57:425–29. https://doi.org/10.1016/j.neuropharm.2009.06.033.
[31] Vámos E, Fejes A, Koch J, Tajti J, Fülöp F, Toldi J, et al. Kynurenate derivative attenuates the nitroglycerin-induced CamKIIα and CGRP expression changes. Headache 2010;50:834–43. https://doi.org/10.1111/j.1526-4610.2009.01574.x.
[32] Chauvel V, Vamos E, Pardutz A, Vecsei L, Schoenen J, Multon S. Effect of systemic kynurenine on cortical spreading depression and its modulation by sex hormones in rat. Exp Neurol 2012;236:207–14. https://doi.org/10.1016/j.expneurol.2012.05.002.
[33] Párdutz Á, Fejes A, Bohár Z, Tar L, Toldi J, Vécsei L. Kynurenines and headache. J Neural Transm 2012;119:285–96. https://doi.org/110.1007/s00702-011-0665-y
[34] Körtési T, Tuka B, Tajti J, Bagoly T, Fülöp F, Helyes Z, et al. Kynurenic Acid Inhibits the Electrical Stimulation Induced Elevated Pituitary Adenylate Cyclase-Activating Polypeptide Expression in the TNC. Front Neurol 2017;8:745. https://doi.org/10.3389/fneur.2017.00745.
[35] Zádori D, Klivényi P, Plangár I, Toldi J, Vécsei L. Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. J Cell Mol Med 2011;15:701–17. https://doi.org/10.1111/j.1582-4934.2010.01237.x.
[36] Kessler M, Terramani T, Lynch G, Baudry M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 1989;52:1319–28.
[37] Birch PJ, Grossman CJ, Hayes AG. Kynurenate and FG9041 have both competitive and non-competitive antagonist actions at excitatory amino acid receptors. Eur J Pharmacol 1988;151:313–5. https://doi.org/10.1016/0014-2999(88)90814-x.
[38] Deen M, Hansen HD, Hougaard A, Nørgaard M, Eiberg H, Lehel S, et al. High brain serotonin levels in migraine between attacks: A 5-HT4 receptor binding PET study. Neuroimage Clin 2018;18:97–102. https://doi.org/10.1016/j.nicl.2018.01.016.
[39] Aggarwal M, Puri V, Puri S. Serotonin and CGRP in migraine. Ann Neurosci 2012;19:88–94. https://doi.org/10.5214/ans.0972.7531.12190210.
[40] Varga H, Párdutz A, Tajti J, Vécsei L, Schoenen J. The modulatory effect of estrogen on the caudal trigeminal nucleus of the rat in an animal model of migraine. Ideggyogy Sz 2006;59:389–95.
[41] Bussone G. Cluster headache: from treatment to pathophysiology. Neurol Sci 2008;29:1-6. https://doi.org/10.1007/s10072-008-0875-8.
[42] Benarroch EE. Locus coeruleus. Cell Tissue Res 2018;373:221–32. https://doi.org/10.1007/s00441-017-2649-1.
[43] Prescott MJ, Lidster K. Improving quality of science through better animal welfare: the NC3Rs strategy. Lab Anim (NY) 2017;46:152–6. https://doi.org/10.1038/laban.1217.
[44] Cseh EK, Veres G, Szentirmai M, Nánási N, Szatmári I, Fülöp F, et al. HPLC method for the assessment of tryptophan metabolism utilizing separate internal standard for each detector. Anal Biochem 2019;574:7–14. https://doi.org/10.1016/j.ab.2019.03.005.
[45] Nánási N, Hadady L, Cseh E, Veres G, Klivényi P, Vécsei L, et al. Development and validation of high performance liquid chromatography method for the measurements of biogenic amines. In: Alapi Tünde, Ilisz István, editors. Proceedings of the 24th International Symposium on Analytical and Environmental Problems, Szeged, University of Szeged; 2018, p. 368–72.
[46] Veres G, Tellér A, Martos D, Szatmari I, Kiss L, Vécsei L, et al. Determination of glutamate and GABA from rat central nervous system samples with HPLC utilizing fluorescent detection. In: Alapi Tünde, Ilisz István, editors. Proceedings of the 25th International Symposium on Analytical and Environmental Problems, 2019. p. 427–31.
[47] Pawlak D, Tankiewicz A, Buczko W. Kynurenine and its metabolites in the rat with experimental renal insufficiency. J Physiol Pharmacol 2001;52:755–66.
[48] Ceresoli-Borroni G, Rassoulpour A, Wu HQ, Guidetti P, Schwarcz R. Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J Neural Transm (Vienna) 2006;113:1355–65. https://doi.org/10.1007/s00702-005-0432-z.
[49] Kucharewicz I, Kasacka I, Pawlak D, Tankiewicz-Kwedlo A, Mroczko B, Buczko W, et al. The concentration of kynurenine in rat model of asthma. Folia Histochem Cytobiol 2008;46:199–203. https://doi.org/10.2478/v10042-008-0030-7.
[50] Sultana N, Arayne MS, Khan MM, Saleem DM, Mirza AZ. Determination of tryptophan in raw materials, rat brain and human plasma by RP-HPLC technique. J Chromatogr Sci 2012;50:531–7. https://doi.org/10.1093/chromsci/bms045.
[51] Zagajewski J, Drozdowicz D, Brzozowska I, Hubalewska-Mazgaj M, Stelmaszynska T, Laidler PM, et al. Conversion L-tryptophan to melatonin in the gastrointestinal tract: the new high performance liquid chromatography method enabling simultaneous determination of six metabolites of L-tryptophan by native fluorescence and UV-VIS detection. J Physiol Pharmacol 2012;63:613–21.
[52] Samavati R, Zádor F, Szűcs E, Tuka B, Martos D, Veres G, et al. Kynurenic acid and its analogue can alter the opioid receptor G-protein signaling after acute treatment via NMDA receptor in rat cortex and striatum. J Neurol Sci 2017;376:63–70. https://doi.org/10.1016/j.jns.2017.02.053.
[53] Wu H-Q, Guidetti P, Goodman JH, Varasi M, Ceresoli-Borroni G, Speciale C, et al. Kynurenergic manipulations influence excitatory synaptic function and excitotoxic vulnerability in the rat hippocampus in vivo. Neuroscience 2000;97:243–51. https://doi.org/10.1016/S0306-4522(00)00030-0.
[54] Saylor D, Steiner TJ. The Global Burden of Headache. Semin Neurol 2018;38:182–90. https://doi.org/10.1055/s-0038-1646946.
[55] Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163–96. https://doi.org/10.1016/S0140-6736(12)61729-2.
[56] GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1603–58. https://doi.org/10.1016/S0140-6736(16)31460-X.
[57] Schuster NM, Rapoport AM. New strategies for the treatment and prevention of primary headache disorders. Nat Rev Neurol 2016;12:635–50. https://doi.org/10.1038/nrneurol.2016.143.
[58] American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 2019;59:1–18. https://doi.org/10.1111/head.13456.
[59] Diener HC, Charles A, Goadsby PJ, Holle D. New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol 2015;14:1010–22. https://doi.org/10.1016/S1474-4422(15)00198-2.
[60] Obermann M, Holle D, Naegel S, Burmeister J, Diener HC. Pharmacotherapy options for cluster headache. Expert Opin Pharmacother 2015;16:1177–84. https://doi.org/10.1517/14656566.2015.1040392.
[61] Sarchielli P, Di Filippo M, Nardi K, Calabresi P. Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr Pain Headache Rep 2007;11:343–51. https://doi.org/10.1007/s11916-007-0216-2.
[62] Bereiter DA, Benetti AP. Excitatory amino release within spinal trigeminal nucleus after mustard oil injection into the temporomandibular joint region of the rat. Pain 1996;67:451–9. https://doi.org/10.1016/0304-3959(96)03156-9.
[63] Lukács M, Warfvinge K, Tajti J, Fülöp F, Toldi J, Vécsei L, et al. Topical dura mater application of CFA induces enhanced expression of c-fos and glutamate in rat trigeminal nucleus caudalis: attenuated by KYNA derivate (SZR72). J Headache Pain 2017;18.39–46. https://doi.org/10.1186/s10194-017-0746-x.
[64] Oshinsky ML, Luo J. Neurochemistry of trigeminal activation in an animal model of migraine. Headache 2006;46: 39-44.
[65] Osikowicz M, Mika J, Przewlocka B. The glutamatergic system as a target for neuropathic pain relief. Exp Physiol 2013;98:372–84. https://doi.org/110.1113/expphysiol.2012.069922.
[66] Bleakman D, Alt A, Nisenbaum ES. Glutamate receptors and pain. Semin Cell Dev Biol 2006;17:592–604. https://doi.org/10.1016/j.semcdb.2006.10.008.
[67] Eide K, Stubhaug A, Oye I, Breivik H. Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain 1995;61:221–8. https://doi.org/10.1016/0304-3959(94)00182-e.
[68] Jevtovic-Todorovic V, Wozniak DF, Powell S, Nardi A, Olney JW. Clonidine potentiates the neuropathic pain-relieving action of MK-801 while preventing its neurotoxic and hyperactivity side effects. Brain Res 1998;781:202–11. https://doi.org/10.1016/s0006-8993(97)01247-x.
[69] Afridi SK, Giffin NJ, Kaube H, Goadsby PJ. A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology 2013;80:642–7. https://doi.org/10.1212/WNL.0b013e3182824e66.
[70] Alt A, Weiss B, Ogden AM, Li X, Gleason SD, Calligaro DO, et al. In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders. Psychopharmacology 2006;185:240–7. https://doi.org/10.1007/s00213-005-0292-0.
[71] Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR, et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 2004;24:596–602. https://doi.org/10.1111/j.1468-2982.2004.00723.x.
[72] Curto M, Lionetto L, Negro A, Capi M, Fazio F, Giamberardino MA, et al. Altered kynurenine pathway metabolites in serum of chronic migraine patients. J Headache Pain 2015;17:47. https://doi.org/10.1186/s10194-016-0638-5.
[73] Curto M, Lionetto L, Negro A, Capi M, Perugino F, Fazio F, et al. Altered serum levels of kynurenine metabolites in patients affected by cluster headache. J Headache Pain 2015;17:27. https://doi.org/10.1186/s10194-016-0620-2.
[74] Schwarcz R. The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol 2004;4:12–7. https://doi.org/10.1016/j.coph.2003.10.006.
[75] Zádori D, Ilisz I, Klivényi P, Szatmári I, Fülöp F, Toldi J, et al. Time-course of kynurenic acid concentration in mouse serum following the administration of a novel kynurenic acid analog. J Pharm Biomed Anal 2011;55:540–3. https://doi.org/10.1016/j.jpba.2011.02.014.
[76] Vécsei L, Szalárdy L, Fülöp F, Toldi J. Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 2013;12:64–82. https://doi.org/10.1038/nrd3793.
[77] Szalardy L, Zadori D, Toldi J, Fulop F, Klivenyi P, Vecsei L. Manipulating kynurenic acid levels in the brain - on the edge between neuroprotection and cognitive dysfunction. Curr Top Med Chem 2012;12:1797–806. https://doi.org/10.2174/156802612803989264
[78] Bohár Z, Párdutz Á, Vécsei L. Tryptophan catabolites and migraine. Curr Pharm Des 2016;22:1013–21.
[79] Vámos E. Protective compounds in animal models of trigeminal activation and neurodegeneration. Ideggyogy Sz 2012;65:64–70.
[80] Messlinger K, Russo AF. Current understanding of trigeminal ganglion structure and function in headache. Cephalalgia 2019;39:1661–74. https://doi.org/10.1177/0333102418786261.
[81] Tuboly G, Tar L, Bohar Z, Safrany-Fark A, Petrovszki Z, Kekesi G, et al. The inimitable kynurenic acid: the roles of different ionotropic receptors in the action of kynurenic acid at a spinal level. Brain Res Bull 2015;112:52–60. https://doi.org/10.1016/j.brainresbull.2015.02.001.
[82] Knyihar-Csillik E, Mihaly A, Krisztin-Peva B, Robotka H, Szatmari I, Fulop F, et al. The kynurenate analog SZR-72 prevents the nitroglycerol-induced increase of c-fos immunoreactivity in the rat caudal trigeminal nucleus: comparative studies of the effects of SZR-72 and kynurenic acid. Neurosci Res 2008;61:429–32. https://doi.org/10.1016/j.neures.2008.04.009.
[83] Park MK, Lee JH, Yang GY, Won KA, Kim MJ, Park YY, et al. Peripheral administration of NR2 antagonists attenuates orofacial formalin-induced nociceptive behavior in rats. Prog Neuro-psychopharmacol Biol Psychiatry 2011;35:982–6. https://doi.org/10.1016/j.pnpbp.2011.01.018.
[84] Veres G, Fejes-Szabó A, Zádori D, Nagy-Grócz G, László AM, Bajtai A, et al. A comparative assessment of two kynurenic acid analogs in the formalin model of trigeminal activation: a behavioral, immunohistochemical and pharmacokinetic study. J Neural Transm (Vienna) 2017;124:99–112. https://doi.org/10.1007/s00702-016-1615-5.
[85] Fejes-Szabó A, Bohár Z, Vámos E, Nagy-Grócz G, Tar L, Veres G, et al. Pre-treatment with new kynurenic acid amide dose-dependently prevents the nitroglycerine-induced neuronal activation and sensitization in cervical part of trigemino-cervical complex. J Neural Transm (Vienna) 2014;121:725–38. https://doi.org/10.1007/s00702-013-1146-2.
[86] Noseda R, Borsook D, Burstein R. Neuropeptides and neurotransmitters that modulate thalamo-cortical pathways relevant to migraine Headache. Headache 2017;57 Suppl 2:97–111. https://doi.org/10.1111/head.13083.
[87] Castle D, Robertson NP. Monoclonal antibodies for migraine: an update. J Neurol 2018;265:1491–2. https://doi.org/10.1007/s00415-018-8886-8.
[88] Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol 2015;79:886–95. https://doi.org/10.1111/bcp.12591.
[89] Raffaelli B, Reuter U. The biology of monoclonal antibodies: focus on calcitonin gene-related peptide for prophylactic migraine therapy. Neurotherapeutics 2018;15:324–35. https://doi.org/10.1007/s13311-018-0622-7.
[90] Vollesen AL, Benemei S, Cortese F, Labastida-Ramírez A, Marchese F, Pellesi L, et al. Migraine and cluster headache – the common link. J Headache Pain 2018;19. https://doi.org/10.1186/s10194-018-0909-4.